Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study
Allen C Cheng, Tom Kotsimbos, Heath A Kelly, Louis B Irving, Simon D Bowler, Simon GA Brown, Mark Holmes, Christine R Jenkins, Philip Thompson, Graham Simpson, Richard Wood-Baker, Sanjaya N Senanayake, Stephen J Brady, David L Paterson, Peter A Wark, John W Upham, Tony M Korman, Dominic E Dwyer, Grant W Waterer, Paul M Kelly
Vaccine | ELSEVIER SCI LTD | Published : 2011
AC has received research funding to perform an investigator-initiated study of influenza vaccine safety from CSL Ltd. SB has received speaker/advisory board fees or travel grants from Astra Zeneca, GSK, and Novartis. DP is on the advisory boards for Merck, AstraZeneca, Leo Pharmaceuticals, Pfizer and Johnson and Johnson; speakers bureau of AstraZeneca, Johnson and Johnson and BioMerieux. Funding: The Australian Government Department of Health and Ageing provided funding for this study via an extension to a National Health and Medical Research Council grant. ACC was funded by a NHMRC Health Professionals Fellowship and PMK by a NHMRC Career Development Award. The funder had input into the data collection instruments as it was based on a public health surveillance system but had no role in the analysis, the writing of the article or decision to publish this paper.